Payment overview · 2025
General Payments
$1,385.70
76 reported records · 16 companies
Healthcare provider profile · identity verified
Terry L Miller, MD
Allopathic & Osteopathic Physicians|Family Medicine · FREEPORT, IL · NPI 1164498366
Verified facts
What the public records show
CMS Open Payments records show Terry L Miller, MD received $1,385.70 in general payments during 2025 across 76 reported records.
PFIZER INC. accounted for 23.0% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 26 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Farxiga, Jardiance, Ozempic, Trelegy Ellipta.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 26 claims for Farxiga by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 17 claims for Jardiance by this doctor in 2024.
E.R. Squibb & Sons, L.L.C. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 27956 records involving 14870 distinct recipient NPIs. Public Medicare Part D data also shows 197 claims for Eliquis by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 22 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 17 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 49 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 44 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 197 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| PFIZER INC. | Unresolved — no canonical attribution shown | $318.96 | 23.0% | 19 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $223.85 | 16.1% | 9 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $168.05 | 12.1% | 10 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $137.10 | 9.9% | 9 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $107.78 | 7.8% | 6 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $106.85 | 7.7% | 5 | 2025 |
| Kowa Pharmaceuticals America, Inc. | Unresolved — no canonical attribution shown | $79.09 | 5.7% | 5 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $57.18 | 4.1% | 4 | 2025 |
| Cranial Technologies, Inc | Unresolved — no canonical attribution shown | $37.81 | 2.7% | 2 | 2025 |
| Insulet Corporation | Unresolved — no canonical attribution shown | $33.28 | 2.4% | 1 | 2025 |
| E.R. Squibb & Sons, L.L.C. | Unresolved — no canonical attribution shown | $25.48 | 1.8% | 1 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $22.24 | 1.6% | 1 | 2025 |
| KYOWA KIRIN, INC. | Unresolved — no canonical attribution shown | $22.10 | 1.6% | 1 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $17.11 | 1.2% | 1 | 2025 |
| Ascensia Diabetes Care Us Inc. | Unresolved — no canonical attribution shown | $14.77 | 1.1% | 1 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $14.05 | 1.0% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $1,385.70 | 76 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $279.10 | 17 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $173.38 | 6 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc., Lilly USA, LLC | $130.02 | 7 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $117.07 | 7 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $114.46 | 5 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $91.15 | 6 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $85.01 | 4 | 2025 |
Source payment records
|
|||||
| ZORYVE Normalized: zoryve |
Drug | Kowa Pharmaceuticals America, Inc. | $79.09 | 5 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | E.R. Squibb & Sons, L.L.C., PFIZER INC. | $66.86 | 4 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $43.00 | 3 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $43.00 | 3 | 2025 |
Source payment records
|
|||||
| Doc Band Normalized: doc band |
Device | Cranial Technologies, Inc | $37.81 | 2 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $37.32 | 2 | 2025 |
Source payment records
|
|||||
| Omnipod Normalized: omnipod |
Device | Insulet Corporation | $33.28 | 1 | 2025 |
Source payment records
|
|||||
| PAXLOVID Normalized: paxlovid |
Drug | PFIZER INC. | $24.70 | 1 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $22.64 | 4 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $22.64 | 4 | 2025 |
Source payment records
|
|||||
| CRYSVITA Normalized: crysvita |
Drug | KYOWA KIRIN, INC. | $22.10 | 1 | 2025 |
Source payment records
|
|||||
| The Cologuard Plus Collection Kit Normalized: the cologuard plus collection kit |
Device | Exact Sciences Corporation | $21.84 | 1 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $17.63 | 1 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $17.11 | 1 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $15.16 | 1 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $15.16 | 1 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $15.16 | 1 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $14.18 | 1 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $14.05 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 197 | exact normalized | Medicare Part D |
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 26 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 17 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 44 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 22 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
26 | suppressed by CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
17 | suppressed by CMS |
| E.R. Squibb & Sons, L.L.C. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 27956 supporting records · 14870 recipient NPIs · example record 1184377713 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
197 | 34 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
22 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
17 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
49 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
44 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
197 | 34 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 531 | 124 |
| Levothyroxine Sodium | Levothyroxine Sodium | 465 | 100 |
| Amlodipine Besylate | Amlodipine Besylate | 464 | 105 |
| Lisinopril | Lisinopril | 386 | 100 |
| Pantoprazole Sodium | Pantoprazole Sodium | 381 | 88 |
| Furosemide | Furosemide | 349 | 76 |
| Metoprolol Tartrate | Metoprolol Tartrate | 316 | 61 |
| Metoprolol Succinate | Metoprolol Succinate | 313 | 79 |
| Potassium Chloride | Potassium Chloride | 284 | 74 |
| Clopidogrel | Clopidogrel Bisulfate | 256 | 54 |
| Xarelto | Rivaroxaban | 254 | 39 |
| Metformin Hcl | Metformin Hcl | 243 | 53 |
| Sertraline Hcl | Sertraline Hcl | 242 | 38 |
| Tamsulosin Hcl | Tamsulosin Hcl | 235 | 54 |
| Cephalexin | Cephalexin | 224 | 127 |
| Gabapentin | Gabapentin | 222 | 51 |
| Bumetanide | Bumetanide | 217 | 49 |
| Celecoxib | Celecoxib | 204 | 53 |
| Eliquis | Apixaban | 197 | 34 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 183 | 48 |
| Valsartan | Valsartan | 179 | 53 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 177 | 80 |
| Famotidine | Famotidine | 176 | 49 |
| Spironolactone | Spironolactone | 171 | 44 |
| Tramadol Hcl | Tramadol Hcl | 164 | 34 |
| Losartan Potassium | Losartan Potassium | 163 | 36 |
| Aripiprazole | Aripiprazole | 161 | 25 |
| Atenolol | Atenolol | 152 | 44 |
| Fluoxetine Hcl | Fluoxetine Hcl | 150 | 27 |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 148 | 17 |
| Escitalopram Oxalate | Escitalopram Oxalate | 144 | 32 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 144 | 38 |
| Omeprazole | Omeprazole | 142 | 37 |
| Prednisone | Prednisone | 139 | 75 |
| Metformin Hcl Er | Metformin Hcl | 137 | 32 |
| Donepezil Hcl | Donepezil Hcl | 134 | 18 |
| Januvia | Sitagliptin Phosphate | 132 | 16 |
| Citalopram Hbr | Citalopram Hydrobromide | 129 | 19 |
| Mirtazapine | Mirtazapine | 128 | 22 |
| Quetiapine Fumarate | Quetiapine Fumarate | 128 | 24 |
| Meloxicam | Meloxicam | 120 | 34 |
| Allopurinol | Allopurinol | 117 | 30 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 103 | 27 |
| Levetiracetam | Levetiracetam | 102 | 13 |
| Cefdinir | Cefdinir | 98 | 86 |
| Glimepiride | Glimepiride | 98 | 25 |
| Duloxetine Hcl | Duloxetine Hcl | 95 | 22 |
| Nebivolol Hcl | Nebivolol Hcl | 95 | 22 |
| Alprazolam | Alprazolam | 89 | 28 |
| Breo Ellipta | Fluticasone/Vilanterol | 84 | 16 |
| Memantine Hcl | Memantine Hcl | 80 | suppressed |
| Lorazepam | Lorazepam | 77 | 27 |
| Simvastatin | Simvastatin | 77 | 18 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 76 | 12 |
| Hydralazine Hcl | Hydralazine Hcl | 69 | 19 |
| Lovastatin | Lovastatin | 67 | 12 |
| Hydrochlorothiazide | Hydrochlorothiazide | 66 | 23 |
| Buspirone Hcl | Buspirone Hcl | 63 | 11 |
| Fluticasone Propionate | Fluticasone Propionate | 56 | 12 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 56 | 40 |
| Carvedilol | Carvedilol | 55 | 15 |
| Naproxen | Naproxen | 55 | 24 |
| Telmisartan | Telmisartan | 55 | 14 |
| Risperidone | Risperidone | 54 | suppressed |
| Latanoprost | Latanoprost | 53 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 52 | 12 |
| Warfarin Sodium | Warfarin Sodium | 51 | 18 |
| Irbesartan | Irbesartan | 50 | 13 |
| Zolpidem Tartrate | Zolpidem Tartrate | 50 | suppressed |
| Amoxicillin | Amoxicillin | 49 | 30 |
| Mounjaro | Tirzepatide | 49 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 48 | 36 |
| Fentanyl | Fentanyl | 48 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 45 | 11 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 45 | 13 |
| Nystatin | Nystatin | 45 | 30 |
| Clonidine Hcl | Clonidine Hcl | 44 | 12 |
| Ozempic | Semaglutide | 44 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 44 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 43 | 12 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 43 | 14 |
| Levofloxacin | Levofloxacin | 42 | 32 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 42 | suppressed |
| Montelukast Sodium | Montelukast Sodium | 37 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 36 | suppressed |
| Olanzapine | Olanzapine | 36 | suppressed |
| Finasteride | Finasteride | 34 | 11 |
| Azithromycin | Azithromycin | 33 | 29 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 33 | 12 |
| Memantine Hcl Er | Memantine Hcl | 33 | suppressed |
| Trazodone Hcl | Trazodone Hcl | 33 | suppressed |
| Clonazepam | Clonazepam | 32 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 32 | 14 |
| Nortriptyline Hcl | Nortriptyline Hcl | 32 | suppressed |
| Toujeo Max Solostar | Insulin Glargine,hum.Rec.Anlog | 32 | suppressed |
| Albuterol Sulfate | Albuterol Sulfate | 31 | 16 |
| Fenofibrate | Fenofibrate,micronized | 31 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 31 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 31 | 12 |
| Tizanidine Hcl | Tizanidine Hcl | 31 | 17 |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 30 | suppressed |
| Cholestyramine | Cholestyramine (With Sugar) | 30 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 30 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 30 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 30 | 17 |
| Pioglitazone Hcl | Pioglitazone Hcl | 30 | suppressed |
| Novolog Flexpen | Insulin Aspart | 29 | suppressed |
| Glipizide Er | Glipizide | 28 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 28 | suppressed |
| Penicillin V Potassium | Penicillin V Potassium | 28 | suppressed |
| Rivastigmine | Rivastigmine | 28 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 27 | suppressed |
| Nabumetone | Nabumetone | 27 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 27 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 26 | 21 |
| Divalproex Sodium Er | Divalproex Sodium | 26 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 26 | suppressed |
| Nifedipine Er | Nifedipine | 26 | suppressed |
| Klor-Con 10 | Potassium Chloride | 25 | suppressed |
| Pregabalin | Pregabalin | 25 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 25 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 25 | suppressed |
| Amantadine | Amantadine Hcl | 24 | suppressed |
| Fenofibrate | Fenofibrate | 24 | suppressed |
| Lamotrigine | Lamotrigine | 24 | suppressed |
| Bupropion Xl | Bupropion Hcl | 23 | suppressed |
| Lubiprostone | Lubiprostone | 23 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 23 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 22 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 22 | suppressed |
| Bupropion Hcl | Bupropion Hcl | 21 | suppressed |
| Diazepam | Diazepam | 21 | suppressed |
| Diltiazem 24hr Er (Xr) | Diltiazem Hcl | 21 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 21 | suppressed |
| Ezetimibe | Ezetimibe | 21 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 20 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 20 | 11 |
| Gemtesa | Vibegron | 20 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 20 | suppressed |
| Ondansetron Odt | Ondansetron | 20 | 17 |
| Risedronate Sodium | Risedronate Sodium | 20 | suppressed |
| Vascepa | Icosapent Ethyl | 20 | suppressed |
| Acyclovir | Acyclovir | 19 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 19 | 15 |
| Clindamycin Hcl | Clindamycin Hcl | 19 | 12 |
| Estradiol | Estradiol | 19 | suppressed |
| Ibandronate Sodium | Ibandronate Sodium | 19 | suppressed |
| Ipratropium-Albuterol | Ipratropium/Albuterol Sulfate | 19 | suppressed |
| Mupirocin | Mupirocin | 19 | 14 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 19 | 13 |
| Verapamil Sr | Verapamil Hcl | 19 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 18 | suppressed |
| Digoxin | Digoxin | 18 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 18 | suppressed |
| Jardiance | Empagliflozin | 17 | suppressed |
| Klor-Con M20 | Potassium Chloride | 17 | suppressed |
| Linzess | Linaclotide | 17 | suppressed |
| Lumigan | Bimatoprost | 17 | suppressed |
| Myrbetriq | Mirabegron | 17 | suppressed |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 16 | suppressed |
| Morphine Sulfate Er | Morphine Sulfate | 16 | suppressed |
| Sucralfate | Sucralfate | 16 | suppressed |
| Desvenlafaxine Succinate Er | Desvenlafaxine Succinate | 15 | suppressed |
| Fluconazole | Fluconazole | 15 | 12 |
| Ibuprofen | Ibuprofen | 15 | suppressed |
| Insulin Glargine-Yfgn | Insulin Glargine-Yfgn | 15 | suppressed |
| Timolol Maleate | Timolol Maleate | 15 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 14 | suppressed |
| Ursodiol | Ursodiol | 14 | suppressed |
| Creon | Lipase/Protease/Amylase | 13 | suppressed |
| Diltiazem 24hr Er | Diltiazem Hcl | 13 | suppressed |
| Trospium Chloride | Trospium Chloride | 13 | suppressed |
| Trulicity | Dulaglutide | 13 | suppressed |
| Budesonide Ec | Budesonide | 12 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 12 | suppressed |
| Folic Acid | Folic Acid | 12 | suppressed |
| Gentamicin Sulfate | Gentamicin Sulfate | 12 | suppressed |
| Ketoconazole | Ketoconazole | 12 | suppressed |
| Methylphenidate Hcl Er (Cd) | Methylphenidate Hcl | 12 | suppressed |
| Minocycline Hcl | Minocycline Hcl | 12 | suppressed |
| Nystop | Nystatin | 12 | suppressed |
| Phenobarbital | Phenobarbital | 12 | suppressed |
| Selenium Sulfide | Selenium Sulfide | 12 | suppressed |
| Vimpat | Lacosamide | 12 | suppressed |
| Apri | Desogestrel-Ethinyl Estradiol | 11 | suppressed |
| Baclofen | Baclofen | 11 | suppressed |
| Benztropine Mesylate | Benztropine Mesylate | 11 | suppressed |
| Jentadueto | Linagliptin/Metformin Hcl | 11 | suppressed |
| Tolterodine Tartrate Er | Tolterodine Tartrate | 11 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $1,385.70 · 76 records | PFIZER INC. | ABRYSVO, AREXVY, COMIRNATY, CRYSVITA, Cologuard Collection Kit, Doc Band, ELIQUIS, EVENITY, FARXIGA, FREESTYLE LIBRE 3, JARDIANCE, Kerendia, NURTEC ODT, OTEZLA, Omnipod, Ozempic, PAXLOVID, PREVNAR 20, REPATHA, Rybelsus, SHINGRIX, TRELEGY ELLIPTA, The Cologuard Plus Collection Kit, Wegovy, ZAVZPRET, ZORYVE | 9 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error